Company intelligence / Profile preview

Evidence Pharmaceuticals

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Evidence Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel therapies for oncology by targeting the tumor microenvironment. The company's lead program, EP-001, is a small molecule inhibitor designed to address hypoxia-driven resistance in solid tumors. By modulating key pathways such as HIF-1α, Evidence Pharmaceuticals aims to enhance the efficacy of existing treatments and provide new options for patients with hard-to-treat cancers. The company is currently advancing its pipeline through early-stage clinical trials to validate its therapeutic approach.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Evidence Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evidence Pharmaceuticals.

Explore the full profile